Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

• Published in: BMC infectious diseases Vol. 21; no. 1; pp. 337 - 8
• Main Authors: Ranjbar, Keivan, Moghadami, Mohsen, Mirahmadizadeh, Alireza, Fallahi, Mohammad Javad, Khaloo, Vahid, Shahriarirad, Reza, Erfani, Amirhossein, Khodamoradi, Zohre, Gholampoor Saadi, Mohammad Hasan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.04.2021; BioMed Central; BMC
• Subjects: Adrenal Cortex Hormones - therapeutic use; Adult; Aged; Blood pressure; Clinical trials; Comparative analysis; Coronaviruses; Corticosteroid; Corticosteroids; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Dexamethasone - therapeutic use; Diabetes; Disease; Drug therapy; Enrollments; Female; Health services; Hospital patients; Hospitalization; Hospitals; Humans; Hypoxia; Infectious diseases; Intervention; Iran; Length of Stay; Male; Methylprednisolone; Methylprednisolone - therapeutic use; Middle Aged; Middle East respiratory syndrome; Mortality; Pathogenesis; Patients; Prospective Studies; Randomized controlled trial; Respiration, Artificial; Respiratory diseases; Severe acute respiratory syndrome coronavirus 2; Steroids; Testing; Treatment Outcome; Vaccines; Viral diseases; Iran; COVID-19; Corticosteroid; Dexamethasone; Methylprednisolone; Randomized controlled trial

Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19...